Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-09-24
2009-12-22
Kaushal, Sumesh (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C424S093200, C424S009200, C435S320100, C435S325000, C435S455000, C536S023100
Reexamination Certificate
active
07635688
ABSTRACT:
The present invention relates generally to viral vaccines and, more particularly, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.
REFERENCES:
patent: 6171596 (2001-01-01), Earl et al.
patent: 6200959 (2001-03-01), Haynes et al.
patent: WO 97/42320 (1997-11-01), None
patent: WO 99/32147 (1999-07-01), None
patent: WO 01/16183 (2001-03-01), None
Baize, Nature Medicine 11(7): 720-721, 2005.
Hampton, JAMA 294(2):163-164, 2005.
Australian Patent Office Communication dated Oct. 25, 2006, pursuant to Australia Patent Application No. 2002327049.
Australian Patent Office Communication dated Nov. 21, 2006, pursuant to Australia Patent Application No. 2005244541.
Sullivan, N.J. et al. 2003 “Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.”Nature424:681-684.
Yang, Z.Y. et al. 2003 “Overcoming immunity to a viral vaccine by DNA priming before vector boosting.”J. Virol.77(1):799-803.
Geisbert, T.W. et al. 2002 “Evaluation in nonhuman primates of vaccines against Ebola virus.”Emerg. Infect. Dis. 8(5):503-507.
Sullivan, N.J. et al. 2000 “Development of a preventive vaccine for Ebola virus infection in primates.”Nature408:605-609.
Pushko, P. et al. 2001 “Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.”J. Virol. 75(23):11677-11685.
Aoki, K. et al. 1999 “Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro,”Mol. Med. 5:224-231.
Baize, S. et al. 1999 “Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients,”Nature Med. 5:423-426.
Bray, M. et al. 1998 “A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever,”J. Infect. Dis. 178:651-661.
Connolly, B.M. et al. 1998 “Pathogenesis of experimental Ebola virus infection in guinea pigs,”J. Infect. Dis. 179:S203-S217.
Davis, A.R. et al. 1985 “Expression of hepatitis B surface antigen with a recombinant adenovirus,”PNAS USA82:7560-7564.
Feldmann, H. et al. 1994 “Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein,”Virology199:469-473.
Fisher-Hoch, S.P. et al. 1985 “Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola),”J. Infect. Dis. 152:887-894.
Hanke, T. et al. 1998 “Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime,”Vaccine16:439-445.
Kiley, M.P. et al. 1980 “Ebola virus: identification of virion structural proteins,”J. Gen. Virol. 49:333-341.
Krieg, A.M. et al. 1995 “CpG motifs in bacterial DNA trigger direct B-cell activation,”Nature374:546-549.
Ksiazek, T.G. et al. 1992 “Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates,”J. Clin. Microbiol. 30:947-950.
Letvin, N.L. et al. 1997 “Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination,”PNAS USA94:9378-9383.
Maryuama, T. et al. 1999 “Ebola virus can be effectively neutralized by antibody produced in natural human infection,”J. Virol. 73:6024-6030.
Natuk, R.J. et al. 1992 “Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model,”PNAS USA89:7777-7781.
Ohno, T. et al. 1994 “Gene therapy for vascular smooth muscle cell proliferation after arterial injury,”Science265:781-784.
Robinson, H.L. et al. 1999 “Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations,”Nature Med. 5:526-534.
Sanchez, A. et al. 1996 “The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing,”PNAS USA93:3602-3607.
Sanchez A. et al. 1998 “Biochemical analysis of the secreted and virion glycoproteins of Ebola virus”J. Virol. 72:6442-6447.
Sato, Y. et al. 1996 “Immunostimulatory DNA sequences necessary for effective intradermal gene immunization,”Science273:352-354.
Schneider, J. et al. 1998 “Enhanced immunogenicity for CD8 + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara,”Nature Med. 4:397-402.
Sedegah, M. et al. 1994 “Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein,”PNAS USA91:9866-9870.
Sedegah, M. et al. 1998 “Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine,”PNAS USA95:7648-7653.
Sullivan, N.J. et al. 2000 “Ebola virus pathogenesis and vaccine development” Symposium on Marburg and Ebola Viruses, Marburg, Germany, Oct. 1-4, 2000, Abstract 23, p. 35.
Tang, D.C. et al. 1992 “Genetic immunization is a simple method for eliciting an immune response,”Nature356:152-154.
Ulmer, J.B. et al. 1993 “Heterologous protection against influenza by injection of DNA encoding a viral protein,”Science259:1745-1749.
Vanderzanden, L. et al. 1998 “DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge,”Virology246:134-144.
Wang, B. et al. 1993 “Gene inoculation generates immune responses against human immunodeficiency virus type 1,”PNAS USA90:4156-4160.
Wilson, J. et al. 2000 “Epitopes involved in antibody-mediated protection from Ebola virus,”Science287:1664-1666.
Xiang, Z.Q. et al. 1996 “A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier,”Virology219:220-227.
Xiang, Z.Q. et al. 1999 “Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant,”J. Immunol. 162:6716-6723.
Xu, L. et al. 1998 “Immunization for Ebola virus infection,”Nature Med. 4:37-42.
Yang, Z. et al. 1998 “Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins”Science279:1034-1037.
Yang, Z. et al. 2000 “Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury”Nature Med. 6:886-889.
Nabel Gary J.
Sanchez Anthony
Sullivan Nancy
Yang Zhi-yong
Kaushal Sumesh
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Development of a preventive vaccine for filovirus infection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Development of a preventive vaccine for filovirus infection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Development of a preventive vaccine for filovirus infection... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4147349